A detailed history of Sherbrooke Park Advisers LLC transactions in Arcturus Therapeutics Holdings Inc. stock. As of the latest transaction made, Sherbrooke Park Advisers LLC holds 11,786 shares of ARCT stock, worth $208,730. This represents 0.06% of its overall portfolio holdings.

Number of Shares
11,786
Holding current value
$208,730
% of portfolio
0.06%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 14, 2025

BUY
$14.82 - $25.48 $174,668 - $300,307
11,786 New
11,786 $200 Million
Q2 2024

Aug 14, 2024

BUY
$24.35 - $44.39 $485,100 - $884,337
19,922 New
19,922 $485 Million

Others Institutions Holding ARCT

About Arcturus Therapeutics Holdings Inc.


  • Ticker ARCT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 26,576,400
  • Market Cap $471M
  • Description
  • Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lun...
More about ARCT
Track This Portfolio

Track Sherbrooke Park Advisers LLC Portfolio

Follow Sherbrooke Park Advisers LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sherbrooke Park Advisers LLC, based on Form 13F filings with the SEC.

News

Stay updated on Sherbrooke Park Advisers LLC with notifications on news.